Asahi Life Asset Management CO. LTD. Buys Shares of 685 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Asahi Life Asset Management CO. LTD. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 685 shares of the biopharmaceutical company's stock, valued at approximately $434,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $30,168,000. Apollon Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 102.9% during the first quarter. Apollon Wealth Management LLC now owns 3,494 shares of the biopharmaceutical company's stock worth $2,216,000 after buying an additional 1,772 shares during the last quarter. Signaturefd LLC lifted its holdings in Regeneron Pharmaceuticals by 5.6% in the first quarter. Signaturefd LLC now owns 2,141 shares of the biopharmaceutical company's stock valued at $1,358,000 after buying an additional 113 shares during the period. Slow Capital Inc. boosted its position in Regeneron Pharmaceuticals by 52.6% during the first quarter. Slow Capital Inc. now owns 19,480 shares of the biopharmaceutical company's stock valued at $12,355,000 after acquiring an additional 6,715 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. boosted its position in Regeneron Pharmaceuticals by 36.2% during the first quarter. Cutter & CO Brokerage Inc. now owns 10,838 shares of the biopharmaceutical company's stock valued at $6,874,000 after acquiring an additional 2,880 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 0.5%

REGN traded up $2.85 on Monday, reaching $570.59. The company's stock had a trading volume of 717,055 shares, compared to its average volume of 1,134,355. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The business's 50 day moving average is $545.22 and its 200 day moving average is $619.17. The stock has a market cap of $61.60 billion, a price-to-earnings ratio of 14.53, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the business posted $9.55 EPS. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research analyst reports. Bank of America cut their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. The Goldman Sachs Group cut their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research report on Monday, June 2nd. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Finally, Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $823.54.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.